{"id":"W3025475588","doi":"10.1136/lba2019.16","title":"P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma","year":2020,"lang":"en","type":"article","venue":"Poster presentations","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital; McMaster University; Juravinski Cancer Centre","funders":"Pfizer","keywords":"Trametinib; Pembrolizumab; Dabrafenib; Medicine; Tolerability; Melanoma; Internal medicine; Oncology; Adverse effect; Vemurafenib; Cancer research; Immunotherapy; MAPK/ERK pathway; Biology; Cancer; Metastatic melanoma; Kinase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005858509,0.0005408216,0.0005791934,0.0002500914,0.0003353802,0.0005858461,0.0007165782,0.0008012857,0.01686637],"category_scores_gemma":[0.0003432095,0.0002643449,0.000854125,0.0002239585,0.0002874279,0.0006724166,0.0003637216,0.001688863,0.002205543],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009314345,"about_ca_system_score_gemma":0.001244667,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001171878,"about_ca_topic_score_gemma":0.00491681,"domain_scores_codex":[0.9998369,0.00004684746,0.00001158298,0.00002702515,0.0000221376,0.0000554326],"domain_scores_gemma":[0.999804,0.0000196588,0.00004767502,0.00001781244,0.00001495017,0.0000960687],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3928938,0.02898782,0.005575504,0.002248513,0.001352575,0.0005152947,0.0001842785,0.002256521,0.1344866,0.001340293,0.05361915,0.3765396],"study_design_scores_gemma":[0.5627002,0.2858581,0.03354073,0.0002577537,0.0009156718,0.001118793,0.0001026278,0.00219349,0.03205771,0.0009231317,0.08025979,0.00007200977],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9221229,0.00863482,0.003843536,0.002231959,0.0006102158,0.01398892,0.01223327,0.000973399,0.03536102],"genre_scores_gemma":[0.9629087,0.00255176,0.004413375,0.001883393,0.0002012399,0.004953325,0.009092219,0.0000867258,0.01390939],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01686637,"threshold_uncertainty_score":0.0564236,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02389815023060663,"score_gpt":0.2698003080044721,"score_spread":0.2459021577738655,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}